Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 10/20 | 0.51 |
| ▸ | FNTB | P49356 | 10/20 | 0.51 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.39 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5959268 | 0.82 | EGFR (0.40) | FNTAFNTBDAOMAPTMCL1 | |
| SCHEMBL27156314 | 0.77 | DAO (0.37) | FNTAFNTBDAOMAPTMCL1 | |
| SCHEMBL27156298 | 0.77 | FNTA (0.53) | FNTAFNTBMAPTKDM4E | |
| SCHEMBL27156309 | 0.75 | FNTA (0.52) | FNTAFNTBALDH1A1KDM4E | |
| SCHEMBL27156308 | 0.75 | NOD2 (0.48) | FNTAFNTBALDH1A1KDM4E | |
| SCHEMBL27156302 | 0.74 | FNTA (0.44) | FNTAFNTBALDH1A1KDM4E | |
| SCHEMBL27156306 | 0.72 | AKR1C3 (0.43) | FNTAFNTBDAOMAPTMCL1 | |
| SCHEMBL27156307 | 0.70 | NR4A1 (0.42) | FNTAFNTBMAPTALDH1A1TSHR | |
| SCHEMBL27156303 | 0.70 | NPC1 (0.37) | FNTAFNTBDAOMAPTALDH1A1 | |
| SCHEMBL5959188 | 0.69 | PTPN1 (0.40) | FNTAFNTBMAPTMCL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11974991-B1 | Adenosine receptor activity of methyl/ethyl 3-(substituted benzoyl)-6,8-dimethylindolizine-2-substituted-1-carboxylates | King Faisal University (SA) | 2024-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11974991-B1 | Adenosine receptor activity of methyl/ethyl 3-(substituted benzoyl)-6,8-dimethylindolizine-2-substituted-1-carboxylates | ADORA2A, ADORA1, ADORA3 | FNTA 1088/4885FNTB 1915/4885DAO 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.